These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
702 related items for PubMed ID: 26327240
1. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. Li M, Zhang L, Ge C, Chen L, Fang T, Li H, Tian H, Liu J, Chen T, Jiang G, Xie H, Cui Y, Yao M, Li J. Oncotarget; 2015 Sep 22; 6(28):25149-60. PubMed ID: 26327240 [Abstract] [Full Text] [Related]
2. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. Chen CL, Tsukamoto H, Liu JC, Kashiwabara C, Feldman D, Sher L, Dooley S, French SW, Mishra L, Petrovic L, Jeong JH, Machida K. J Clin Invest; 2013 Jul 22; 123(7):2832-49. PubMed ID: 23921128 [Abstract] [Full Text] [Related]
3. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X. Cancer Lett; 2017 Jul 10; 398():12-21. PubMed ID: 28377178 [Abstract] [Full Text] [Related]
10. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Li Y, Jiang F, Liu Q, Shen J, Wang X, Li Z, Zhang J, Lu X. Toxicol Sci; 2015 Jan 10; 143(1):156-64. PubMed ID: 25304214 [Abstract] [Full Text] [Related]
13. CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells. Wang H, Qian Z, Zhao H, Zhang X, Che S, Zhang H, Shang H, Bao J, Hao C, Liu J, Li Z. Mol Med Rep; 2015 Sep 10; 12(3):3902-3908. PubMed ID: 26035694 [Abstract] [Full Text] [Related]
14. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C. Cancer Lett; 2016 Feb 28; 371(2):171-81. PubMed ID: 26655273 [Abstract] [Full Text] [Related]
15. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X. Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740 [Abstract] [Full Text] [Related]
16. Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells. Wilson GS, Hu Z, Duan W, Tian A, Wang XM, McLeod D, Lam V, George J, Qiao L. Stem Cells Dev; 2013 Oct 01; 22(19):2655-64. PubMed ID: 23638793 [Abstract] [Full Text] [Related]
18. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma. Hou H, Sun H, Lu P, Ge C, Zhang L, Li H, Zhao F, Tian H, Zhang L, Chen T, Yao M, Li J. Mol Cancer Ther; 2013 Dec 01; 12(12):2874-84. PubMed ID: 24130050 [Abstract] [Full Text] [Related]
19. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma. Hua L, Hu B, Yan D, Liu J, Shen Y, Zhao F, Shen C, Chen B, Cui X. Pathol Res Pract; 2017 Jun 01; 213(6):688-697. PubMed ID: 28476378 [Abstract] [Full Text] [Related]
20. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Jiang Y, He Y, Li H, Li HN, Zhang L, Hu W, Sun YM, Chen FL, Jin XM. Gastric Cancer; 2012 Oct 01; 15(4):440-50. PubMed ID: 22395309 [Abstract] [Full Text] [Related] Page: [Next] [New Search]